一吻定情

New Release Date for Mammootty's Kalamkaval Revealed_我的网站

一 |     　　三星电子股价大跳水。    The makers of Kalamkaval have officially confirmed that the film will now arrive in theatres on December 5. The announcement comes after the team reviewed the final stage of post-production and decided that the film would benefit from a slightly later window. The move follows earlier communication from the production house that hinted at a stronger and more precise theatrical plan.     A new date and a clearer rollout plan     Kalamkaval features Mammootty and Vinayakan in central roles. Mammootty is believed to play a morally complex character whose motivations drive the core tension, while Vinayakan appears as a police officer whose track intersects with the unfolding drama. The pairing has already created interest, especially as both actors are known for grounded and unpredictable performances.     The film marks the directorial debut of Jithin K Jose, who previously wrote the story for Kurup. The screenplay is co-written by Jithin and Jishnu Sreekumar. With this project, Jithin steps into a more expansive creative role, shaping a thriller that leans heavily on atmosphere and shifting moral lines.     Cast, craft and tone     The supporting cast includes Jibin Gopinath, who earned attention for his recent turn in Dies Irae. The team behind the film features cinematographer Faisal Ali, editor Praveen Prabhakar, composer Mujeeb Majeed and production designer Shajie Naduvil. Their combined craftsmanship is expected to lend the film its moody palette and grounded visual identity.     Kalamkaval has received a U/A 16+ certification, signalling a tone that remains intense while still accessible to a broad audience. Early stills and teasers hinted at a narrative that draws from real world textures and psychological unease. With the release pushed into December, the makers are positioning the film for a more focused promotion cycle.                                                                 View this post on Instagram          A post shared by Mammootty Kampany (@mammoottykampany)                         Produced by Mammootty Kampany and distributed in Kerala by Wayfarer Films, Kalamkaval now moves into the final leg of its campaign. The December 5 release is set to give the film a clearer corridor at the box office and a more cohesive buildup. For viewers, the revised date offers a more confident sense of when the long-awaited thriller will finally unfold on screen.Also Read: South Indian Legends Mourn Dharmendra。

二 |
　　今日早间，韩国股市开盘后，三星电子股价大幅跳水，一度大跌超7%。在此之前，三星电子宣布计划在第三季度派发约30万亿韩元现金股息，预计2026年股东回报资金将达到约90万亿至110万亿韩元。

三 | 　　高盛在最新发布的报告中指出，AI（人工智能）交易的“躺赢”时代或许已经结束，开始进入了一个更加依赖基本面、盈利预期和估值错配的阶段。高盛还表示，存储板块和数据中心板块的估值缺口最为突出，是目前最具吸引力的战术性机会。

四 | 　　三星电子跳水　　北京时间8月24日早间，韩国股市开盘后，三星电子股价直线跳水，盘初一度大跌超7%，截至北京时间8:30，跌幅达6.84%。受此拖累，韩国KOSPI指数跌1.89%。SK海力士则小幅走高，现涨0.35%。　　消息面上，三星电子此前公布了史上规模最大的股东回报计划，预计2026年向股东返还最多110万亿韩元（约合人民币5300亿元），相当于自由现金流的五成左右。　　据三星电子向监管机构提交的文件，公司将派发约30万亿韩元第三季度现金股息，并回购约15万亿韩元股票用于员工薪酬计划。　　Petra Capital Management管理合伙人兼首席投资官Albert Yong表示：“市场真正关注的问题在于增量规模有多大，以及回购与股息各占多少比例。”　　目前，三星电子尚未公布回报计划的具体结构细节，股息与回购的比例仍有待明确。

五 | 具体细节或将在10月下旬的董事会上最终确定。　　此次三星电子公布的股东回报规模若最终落于110万亿韩元上限，将刷新韩国企业股东回报的历史纪录，进一步检验韩国上市公司能否在AI周期带来的超额利润中，持续扩大对投资者的现金分配比例。　　KB证券此前预计，未来3年三星电子的股东回报总规模至少将达到600万亿至700万亿韩元，按现金分红计算的股息率将达到7%至15%。　　在三星电子公布股东回报计划前，SK海力士也宣布了40万亿韩元回购计划，并将2025年至2027年间产生的超过50%自由现金流用于提升股东回报。　　市场预计，三星电子和SK海力士到2026年年底将持有总计2630亿美元的净现金储备。据LSEG数据和路透测算，这一数字是英伟达预估净现金（1020 亿美元）的两倍有余，同时也超过美股 “科技七巨头” 其余六家科技企业的现金总和。　　高盛最新研判　　高盛在最新发布的报告中指出，目前AI交易的叙事逻辑正经历快速切换：随着算力成本持续下行，市场的关注焦点已从“谁是大规模资本开支的赢家”转向“谁是AI大规模普及浪潮中的真正受益者”。　　高盛表示，当前的仓位出清叠加依然强劲的AI基本面，为9月份市场重新承担风险奠定了更为健康的基础。　　高盛认为，AI交易远未终结，但AI交易已经从过去的“普涨行情”，进入了一个更加依赖基本面、盈利预期和估值错配的阶段。　　在战术层面，高盛建议围绕“股价与每股盈利大幅背离”的机会进行交易，并指出存储板块和数据中心板块的估值缺口最为突出，是目前最具吸引力的战术性机会。　　从高盛编制的加权平均净利润预期与加权平均市值对比来看，上述两个板块的盈利修复尚未充分反映在股价之中。　　高盛表示，英伟达二季度财报是下一个关键催化剂，此后密集的9月行业会议季也将为市场提供重要支撑。　　据彭博报道，英伟达部分大型客户已经被告知，搭载英伟达AI芯片的服务器系统明年初开始可能涨价超过15%，主要原因就是内存芯片成本快速上涨。这再次证明存储产业链的议价权。　　与此同时，AI应用层正逐步获得市场关注。Moderna与默沙东此前宣布合作开发AI辅助药物，引发市场对医疗健康AI赛道的广泛兴趣。　　高盛数据显示，医疗AI受益标的的盈利修正广度正在提升，专业投资者情绪的改善也开始带动泛型投资者入场布局AI药物研发相关机会。　　东财图解·加点干货（文章来源：券商中国）。

六 |

Current article:http://l7hp1t1.linlangdouwaqiexusan.bond/uq24s/20260826/5208.html

Published on:17:34:25